This FDA label expansion is a significant catalyst that should drive revenue growth by adding a new pediatric segment to Joenja's addressable market. Monitor the separate sNDA for lower-weight pediatric patients (13kg to <27kg) as a potential further catalyst.
Drug in focus
PHAR drug pipeline →Joenja
▲ Bullish Named in this 6-K- Impact
- Phase
- Approved
- Time to market
- Already approved and commercializing (first FDA approval March 2023). Label expansion for children 4-11 approved September 2026 with new doses available October 2026. EU launch starting Germany Q3 2026.
- Next catalyst
- None dated
What to watchJoenja's commercial ramp is the key story, watch quarterly Joenja revenue growth, EU launch uptake (starting Germany Q3 2026), and the pending sNDA for lower-weight pediatric patients (13kg to <27kg) submitted July 30, 2026. Phase 3 topline data for ages 1-6 (trial NCT05693129, primary completion July 2026) and Phase 2 CVID data (expected Q4 2026) are potential catalysts. The stock's 52-week low of $9.62 vs. analyst mean target of $34.35 suggests deep value if Joenja execution holds, but the company also faces headwinds from RUCONEST decline and recent revenue guidance cuts.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 11 $11.21entry
- T+1 · 2mo ago −3.48%α −3.03% · $10.82
- T+5 · 2mo ago −5.89%α −5.67% · $10.55
- T+20 · 6w ago −12.67%α −14.54% · $9.79
- T+46 · todayOpen
- T+60 · in 20d Pending
Price Chart
How similar events traded
Executive Summary
Pharming announced FDA approval of its sNDA for Joenja (leniolisib) to treat children aged 4-11 years with APDS, expanding the label from the prior 12+ age group. This is a clear regulatory catalyst that opens a new pediatric patient segment, with new doses expected to be available in October 2026. A separate sNDA for lower-weight pediatric patients (13kg to <27kg) was also submitted on July 30, 2026, indicating a broader pipeline expansion strategy.
Key Facts
- FDA approved Joenja (leniolisib) for children aged 4-11 years weighing at least 27kg with APDS
- First FDA-approved treatment for this pediatric APDS population in the U.S.
- Newly approved 40mg and 50mg doses expected to be available in October 2026
- A separate sNDA for lower-weight pediatric patients (13kg to <27kg) was submitted on July 30, 2026
- Approval supported by Phase III open-label study showing improvements in lymphadenopathy and naïve B cells over 12 weeks
- Safety profile consistent with prior Joenja experience; no drug-related serious adverse events observed
Financial Impact
Expands addressable APDS patient population to include children aged 4-11 years; APDS affects approximately 1-2 per million worldwide. No specific revenue figures provided in the filing.
Risk Factors
- Competition from other PI3K inhibitors or emerging APDS therapies
- Commercial uptake may be slower than expected if payer coverage or physician adoption lags
- The separate sNDA for lower-weight pediatric patients may face regulatory hurdles or delays
- Joenja's safety profile includes neutropenia (33% of patients 12+ and 63% of patients 4-12 developed ANC 500-1500 cells/microL)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001828316-26-000037 |
| Document: 0001828316-26-000037-index-headers.html | 0001828316-26-000037 |
| Document: 0001828316-26-000037-index.html | 0001828316-26-000037 |
| Document: 0001828316-26-000037.txt | 0001828316-26-000037 |
Track record
18 reports on PHAR
9 of 14 bullish or bearish reports moved the stock their way by T+5. Best: +39.00% at T+20 after the Oct 14, 2026 report. 11 of 14 went positive at some point.
Filters
- Nov 6, 202610d ago 6-K Bullish 5/10 Entry $12.29 to $12.60 Now $12.59 +2.44% ▲ +2.52% −0.07% vs SPY
- Nov 6, 202611d ago Press Release Bullish 6/10 Entry $12.29 to $12.60 Now $12.59 +2.44% ▲ +2.52% −0.07% vs SPY
- Oct 27, 202620d ago 6-K Bullish 6/10 No price data
- Oct 27, 202621d ago Press Release Bullish 6/10 Entry $11.87 to $12.93 Now $12.59 +6.07% ▲ +8.93% +10.92% vs SPY
- Oct 22, 202625d ago 6-K Bullish 6/10 Entry $10.67 to $11.86 Now $12.59 +17.99% ▲ +11.15% +10.45% vs SPY
- Oct 14, 20264w ago 6-K Bullish 6/10 Entry $9.64 to $9.65 Now $12.59 +30.60% ▲ +0.10% −0.35% vs SPY
- Sep 29, 20266w ago 6-K Bearish 5/10 Entry $10.01 to $9.68 Now $12.59 −25.77% ▲ +3.30% +5.25% vs SPY
- Sep 29, 20267w ago Press Release Bearish 6/10 Entry $10.01 to $9.68 Now $12.59 −25.77% ▲ +3.30% +5.25% vs SPY
- Sep 25, 20267w ago 6-K Bullish 6/10 Entry $10.46 to $9.75 Now $12.59 +20.36% ▼ −6.79% −6.57% vs SPY
- Sep 25, 20267w ago Press Release Bullish 5/10 Entry $10.46 to $9.75 Now $12.59 +20.36% ▼ −6.79% −6.57% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers